Brokerages expect that Imv Inc (NYSE:IMV) will post ($0.11) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for IMV’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.10). IMV reported earnings of ($0.06) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 83.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, May 13th.

According to Zacks, analysts expect that IMV will report full year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.36). For the next fiscal year, analysts forecast that the business will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.38) to ($0.12). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for IMV.

IMV (NYSE:IMV) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $0.10 million during the quarter.

A number of equities research analysts have issued reports on the company. Raymond James set a $10.00 price target on IMV and gave the company an “outperform” rating in a research report on Monday, March 25th. Zacks Investment Research lowered IMV from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Finally, HC Wainwright began coverage on IMV in a research report on Monday, March 25th. They set a “buy” rating and a $11.50 target price on the stock. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.75.

Hedge funds and other institutional investors have recently modified their holdings of the company. Ipswich Investment Management Co. Inc. acquired a new stake in shares of IMV during the 4th quarter worth about $34,000. Ruffer LLP acquired a new stake in shares of IMV during the 4th quarter worth about $31,305,000. Hartford Financial Management Inc. raised its position in shares of IMV by 15.0% during the 4th quarter. Hartford Financial Management Inc. now owns 26,850 shares of the company’s stock worth $139,000 after acquiring an additional 3,500 shares in the last quarter. Finally, First Manhattan Co. raised its position in shares of IMV by 75.7% during the 1st quarter. First Manhattan Co. now owns 154,518 shares of the company’s stock worth $620,000 after acquiring an additional 66,550 shares in the last quarter.

IMV stock traded down $0.29 during mid-day trading on Wednesday, reaching $3.21. The company had a trading volume of 59,941 shares, compared to its average volume of 27,080. IMV has a fifty-two week low of $3.44 and a fifty-two week high of $7.21.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Featured Story: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.